Erin A. Nekritz - Publications

Affiliations: 
University of California, San Francisco, San Francisco, CA 

13 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Kumar P, Koach J, Nekritz E, Mukherjee S, Braun BS, DuBois SG, Nasholm N, Haas-Kogan D, Matthay KK, Weiss WA, Gustafson C, Seo Y. Aurora Kinase A inhibition enhances DNA damage and tumor cell death with I-MIBG therapy in high-risk neuroblastoma. Ejnmmi Research. 14: 54. PMID 38869684 DOI: 10.1186/s13550-024-01112-7  0.564
2024 Kumar P, Koach J, Nekritz E, Mukherjee S, Braun BS, DuBois SG, Nasholm N, Haas-Kogan D, Matthay KK, Weiss WA, Gustafson C, Seo Y. Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma. Research Square. PMID 38313265 DOI: 10.21203/rs.3.rs-3845114/v1  0.582
2017 Rodriguez-Barrueco R, Nekritz EA, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke TZ, Gorbatenko A, Birnbaum D, Ezhkova E, Cordon-Cardo C, Finetti P, Llobet-Navas D, Silva JM. miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes & Development. 31: 553-566. PMID 28404630 DOI: 10.1101/Gad.292318.116  0.338
2016 Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Parisi MT, Shulkin BL, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, et al. Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. European Journal of Nuclear Medicine and Molecular Imaging. PMID 27044383 DOI: 10.1007/S00259-016-3381-X  0.356
2015 Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. European Journal of Nuclear Medicine and Molecular Imaging. PMID 26338179 DOI: 10.1007/S00259-015-3179-2  0.378
2015 DuBois SG, Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson C, Lin L, Giacomini K, Naranjo A, Ryn CV, Yanik GA, Kreissman SG, Hogarty MD, Matthay KK. Vesicular monoamine transporter protein expression in neuroblastoma: A report from the Children’s Oncology Group. Journal of Clinical Oncology. 33: 10043-10043. DOI: 10.1200/Jco.2015.33.15_Suppl.10043  0.397
2014 Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 26: 414-27. PMID 25175806 DOI: 10.1016/J.Ccr.2014.07.015  0.569
2014 Gustafson WC, Meyerowitz JG, Nekritz EA, Charron E, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA. Abstract PR08: Drugging MYCN protein stability through an allosteric transition in Aurora kinase A Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Pr08  0.601
2014 Meyerowitz JG, Gustafson WC, Nekritz E, Swartling F, Shokat KM, Ruggero D, Weiss WA. Abstract B78: Targeting the translational apparatus in MYCN-driven medulloblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B78  0.594
2014 Gustafson WC, Meyerowitz JG, Nekritz EA, Charron EA, Chanthery Y, Simonds E, Matthay K, Hertz N, Shokat K, Weiss WA. Abstract 2688: Drugging MYCN through an allosteric transition in Aurora A kinase Cancer Research. 74: 2688-2688. DOI: 10.1158/1538-7445.Am2014-2688  0.594
2013 Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, Mcdermott U, Benes CH, Kung AL, Weiss WA, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition Cancer Discovery. 3: 309-323. PMID 23430699 DOI: 10.1158/2159-8290.Cd-12-0418  0.562
2013 Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, et al. Abstract 4622: Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Research. 73: 4622-4622. DOI: 10.1158/1538-7445.Am2013-4622  0.558
2012 Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, VanBrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 14: 735-42. PMID 22382618 DOI: 10.1007/S11307-012-0552-4  0.471
Show low-probability matches.